Kristin Yarema - 11 Jun 2021 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role: Chief Commercial Officer
Signature: /s/ David Tucker, Attorney-in-Fact for Kristin Yarema
Issuer symbol: ATRA
Transactions as of: 11 Jun 2021
Net transactions value: +$500,370
Form type: 4
Filing time: 15 Jun 2021, 16:02:31 UTC
Previous filing: 20 May 2021
Next filing: 03 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATRA	Common Stock	Purchase	$29,304	+2,021	+2.2%	$14.50^*	93,549	11 Jun 2021	Direct	F1
transaction	ATRA	Common Stock	Purchase	$50,680	+3,500	+3.7%	$14.48^*	97,049	14 Jun 2021	Direct	F1
transaction	ATRA	Common Stock	Purchase	$420,385	+28,833	+30%	$14.58^*	125,882	14 Jun 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person's sale of ATRA common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 761 shares, with the reporting person's sale of 761 shares of ATRA common stock at a weighted average price of $14.55 per share on May 18, 2021. The reporting person has agreed to pay to ATRA $53.27, representing the full amount of the profit realized in connection with the short-swing transaction.

Content

The reporting person's sale of ATRA common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 761 shares, with the reporting person's sale of 761 shares of ATRA common stock at a weighted average price of $14.55 per share on May 18, 2021. The reporting person has agreed to pay to ATRA $53.27, representing the full amount of the profit realized in connection with the short-swing transaction.